Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal RNA-processing protein 8 (RRP8), also known as nucleomethylin (NML), is a highly conserved nucleolar methyltransferase enzyme essential for ribosome biogenesis. RRP8 catalyzes N¹-methyladenosine (m¹A) modification in rRNA (28S rRNA in humans; 25S rRNA in yeast), a modification critical for the formation of functional 60S ribosomal subunits. Beyond its methyltransferase activity, RRP8/NML coordinates ribosome production with nutrient availability via the energy-dependent nucleolar silencing complex, affecting rRNA transcription and cellular proliferation. Loss of RRP8 disrupts ribosome assembly, activates p53, and leads to cell cycle arrest. In humans, RRP8 also functions as an autoantigen in systemic lupus erythematosus, especially lupus nephritis, highlighting its relevance for autoimmunity and potential use as a biomarker.
Not applicable (no direct drugs); likely mechanisms for a potential inhibitor would involve inhibition of methyltransferase activity, leading to defects in ribosomal subunit maturation and altered cell proliferation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal RNA-processing protein 8 (RRP8).